Cost-effectiveness of New Tuberculosis Vaccines in Zambia
Author Information
Author(s): Tseng Chia-Lin, Oxlade Olivia, Menzies Dick, Aspler Anne, Schwartzman Kevin
Primary Institution: McGill University
Hypothesis
Can novel vaccines for tuberculosis control be cost-effective compared to existing strategies in Zambia?
Conclusion
Investing in an improved TB vaccine is expected to lead to significant cost savings and a reduction in TB-related morbidity and mortality.
Supporting Evidence
- A BCG replacement vaccine could prevent 932 TB cases and 422 deaths over 30 years.
- The prime-boost strategy could avert 1,863 TB cases and 1,011 deaths.
- Net savings of $3.6 million are expected with vaccination at birth alone.
- Total costs for the prime-boost strategy are projected to be lower in the long run.
Takeaway
This study shows that a new TB vaccine could save money and help more people by preventing TB disease and deaths.
Methodology
A decision analysis model-based simulation was conducted from a societal perspective over a 30-year period.
Limitations
The analysis may underestimate costs and benefits due to the prorated attribution of initial vaccine development costs to Zambia.
Participant Demographics
The study focused on newborns in Zambia, a country with high HIV prevalence and TB incidence.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website